Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre, shared a post on LinkedIn:
“Lutetium-177 DOTATOC vs. everolimus (COMPETE Trial) in The Lancet
Another HUGE win for Theranostics.
First site activated globally was Peter MacCallum Cancer Centre in Dec 2016. Congrats Prof Michael Michael and A/Prof Grace Kong and the NETS team… a decade in the making!
Progression-free survival longer with Lu-177: 24 vs. 14 months, with much LESS side effects.
Objective response rate: 22% vs. 4%
Patient reported quality-of-life: +1 vs. -10 (global health status)
All endpoints favour Lutetium-177.”
Title: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Authors: Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard Baum, Hein Verberne, Jarosław Ćwikła, Rajaventhan Srirajaskanthan, Louis de Mestier, Chiara Grana, Andreas Buck, Dieter Hörsch, Marianne Pavel, Lawrence Dierickx, Michael Michael, Jonathan Strosberg, Attila Kollár, Paula Jimenez-Fonseca, Anja Rinke, Maribel del Olmo-García, Anthime Flaus, Jorge Hernando, Andreas Kluge, Monika Breuninger, Serhii Melnyk, Konstantin Zhernosekov, Jaume Capdevila
Read the Full Article on The Lancet
Other articles featuring Michael Hofman on OncoDaily